[1]王敏,李谦,包小敏,等.质子泵抑制剂联合强化饮食干预治疗咽喉反流性疾病的有效性研究[J].第三军医大学学报,2019,41(21):2107-2113.
 WANG Min,LI Qian,BAO Xiaomin,et al.Efficacy of proton pump inhibitors combined with intensive diet intervention in treatment of laryngopharyngeal reflux disease[J].J Third Mil Med Univ,2019,41(21):2107-2113.
点击复制

质子泵抑制剂联合强化饮食干预治疗咽喉反流性疾病的有效性研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第21期
页码:
2107-2113
栏目:
临床医学
出版日期:
2019-11-15

文章信息/Info

Title:
Efficacy of proton pump inhibitors combined with intensive diet intervention in treatment of laryngopharyngeal reflux disease
作者:
王敏1李谦1包小敏1张焱1冯筱青2邓梦惠1周朗朗1 邓安春
1400037 重庆,陆军军医大学(第三军医大学)第二附属医院:耳鼻咽喉科1,营养科2
Author(s):
WANG Min1 LI Qian1 BAO Xiaomin1 ZHANG Yan1 FENG Xiaoqing2 DENG Menghui1 ZHOU Langlang1 DENG Anchun1

1Department of Otorhinolaryngology, 2Department of Clinical Nutrition, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
咽喉反流质子泵抑制剂饮食干预治疗
Keywords:
laryngopharyngeal reflux proton pump inhibitors diet intervention treatment
分类号:
R459.3; R766.5; R975.6
文献标志码:
A
摘要:

目的比较质子泵抑制剂(proton pump inhibitors, PPI)联合强化饮食干预对比单用质子泵抑制剂治疗咽喉反流疾病的有效性。方法将2017年1月至2018年1月在我院诊断为咽喉反流性疾病210例患者,分成强化饮食干预组(n=110)和标准饮食组(n=100)。强化饮食干预组采用规范化抑酸治疗联合强化饮食干预,而标准饮食组仅采用规范化抑酸治疗和普通饮食,两组均治疗12周。治疗前后采用反流症状指数量表(reflux symptom index,RSI)和反流体征评分量表(reflux finding score,RFS)进行评分。结果 两组年龄、性别及治疗前RSI和RFS评分均无统计学差异。经过8周治疗,强化饮食干预组和标准饮食组均能有效改善患者RSI(P<0.01)和RFS评分(P<0.01)。与标准饮食组相比,强化饮食干预组能进一步降低RSI和RFS评分,特别在改善持续清嗓,痰过多或鼻涕倒流,饭后或躺下后咳嗽和烧心、胸痛、胃痛4个症状更为明显,差异有统计学意义(P<0.05)。在总体有效率方面,治疗8周后,强化饮食干预组和标准饮食组有效率分别为73.07%和70.21%;治疗12周后,强化饮食干预组和标准饮食组有效率分别为83.67%和80.00%,但差异均无统计学意义。 结论与单用PPI药物相比,PPI药物联合强化饮食干预能进一步改善咽喉反流性疾病患者的RSI和RFS评分,提高总体有效率。
 

Abstract:

ObjectiveTo compare the efficacy of proton pump inhibitors (PPI) combined with intensive diet intervention vs PPI alone in the treatment of laryngopharyngeal reflux disease (LPRD). MethodsA total of 210 patients diagnosed with LPRD in our hospital during January 2017 and January 2018 were recruited in this study, and were divided into PPI with intensive diet intervention group (PPI+diet group, n=110) and PPI group (n=100). The PPI+diet group received standardized acid suppression therapy and intensified dietary intervention, while the PPI group only received standardized acid suppression therapy and standard diet. Both groups were treated for 12 weeks. Reflux symptom index (RSI) and reflux symptoms score (RFS) was used to evaluate the efficacy before and after treatment. ResultsThere were no statistical differences in age, sex and RSI and RFS scores between the 2 groups. After 8 weeks of treatment, the RSI (P<0.01) and RFS (P<0.01) scores were significantly improved in both PPI plus diet group and PPI group. As compared with the PPI group, the PPI plus intensive diet group had lower RSI and RFS scores (P<0.05), especially in improving the symptoms of throat clearing, postnasal drip, cough and heartburn, chest pain and coughing post-eating or lying down. For the overall effective rate, the effective rate in PPI plus diet group and PPI group was 73.07% and 70.21% after 8 weeks of treatment, and the effective rate was improved to 83.67% and 80.00% after 12 weeks, although there were no significant differences. ConclusionCompared with PPI alone , PPI combined with intensive diet intervention can more significantly improve the RSI and RFS scores of LPRD patients with higher overall efficiency.

参考文献/References:

[1]CAMPAGNOLO A M, PRISTON J, THOEN R H, et al. Laryngopharyngeal reflux: diagnosis, treatment, and latest research[J]. Int Arch Otorhinolaryngol, 2014, 18(2): 184-191. DOI:10.1055/s-0033-1352504.
[2]LECHIEN J R, SAUSSEZ S, KARKOS P D. Laryngopharyngeal reflux disease: clinical presentation, diagnosis and therapeutic challenges in 2018[J]. Curr Opin Otolaryngol Head Neck Surg, 2018, 26(6): 392-402. DOI:10.1097/MOO.0000000000000486.
[3]LECHIEN J R, FINCK C, KHALIFE M, et al. Change of signs, symptoms and voice quality evaluations throughout a 3- to 6-month empirical treatment for laryngopharyngeal reflux disease[J]. Clin Otolaryngol, 2018, 43(5): 1273-1282. DOI:10.1111/coa.13140.
[4]SPANTIDEAS N, DROSOU E, BOUGEA A, et al. Laryngopharyngeal reflux disease in the Greek general population, prevalence and risk factors[J]. BMC Ear Nose Throat Disord, 2015, 15: 7. DOI:10.1186/s12901-015-0020-2.
[5]CHEN X M, LI Y, GUO W L, et al. Prevalence of laryngopharyngeal reflux disease in Fuzhou region of China[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(12):909-913.DOI:10.3760/cma.j.issn.1673-0860.2016.12.006.
[6]LIU C, WANG H, LIU K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux[J]. Braz J Med Biol Res, 2016, 49(7):e5149.DOI:10.1590/1414-431X20165149.
[7]KOUFMAN J A. Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications[J]. Ann Otol Rhinol Laryngol, 2011, 120(5): 281-287. DOI:10.1177/000348941112000501.
[8]ZALVAN C H, HU S, GREENBERG B, et al. A comparison of alkaline water and Mediterranean diet vs proton pump inhibition for treatment of laryngopharyngeal reflux[J]. JAMA Otolaryngol Head Neck Surg, 2017, 143(10): 1023-1029. DOI:10.1001/jamaoto.2017.1454.
[9]BELAFSKY P C, POSTMA G N, KOUFMAN J A. Validity and reliability of the reflux symptom index (RSI)[J]. J Voice, 2002, 16(2): 274-277.
[10]史信. 《中国居民膳食指南(2016)》发布[J]. 中国妇幼健康研究, 2016, 27(5): 670.
SHI X. Released of the Dietary Guidelines for Chinese Residents (2016)[J]. Chin J Woman Child Heal Res, 2016, 27(5): 670.
[11]LECHIEN J R, HUET K, KHALIFE M, et al. Alkaline, protein, low-fat and low-acid diet in laryngopharyngeal reflux disease: Our experience on 65 patients[J]. Clin Otolaryngol, 2019, 44(3): 379-384. DOI:10.1111/coa.13269.
[12]李进让,肖水芳,李湘平,等. 咽喉反流性疾病诊断与治疗专家共识(2015年)解读[J]. 中华耳鼻咽喉头颈外科杂志, 2016,51(5):327-332.DOI:10.3760/cma.j.issn.1673-0860.2016.05.002.
LI J R, XIAO S F, LI X P, et al. Explanation of the experts consensus on diagnosis and treatment of laryngopharyngeal reflux disease (2015)[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016,51(5):327-332. DOI:10.3760/cma.j.issn.1673-0860.2016.05.002.
[13]FORD C N. Evaluation and management of laryngopharyngeal reflux[J]. JAMA, 2005, 294(12): 1534-1540. DOI:10.1001/jama.294.12.1534.
[14]REMACLE M, LAWSON G. Diagnosis and management of laryngopharyngeal reflux disease[J]. Curr Opin Otolaryngol Head Neck Surg, 2006, 14(3): 143-149. DOI:10.1097/01.moo.0000193189.17225.91.
[15]BATIOGLU-KARAALTIN A, DEVELIOGLU O, AKINER U, et al. Diagnosis and treatment of laryngopharyngeal reflux: Use of empirical lansoprazole[J]. Ear Nose Throat J, 2018, 97(12): E1-E6.
[16]CARROLL T L, WERNER A, NAHIKIAN K, et al. Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease[J]. Laryngoscope, 2017, 127(Suppl 6): S1-S13. DOI:10.1002/lary.26806.
[17]BRISEBOIS S, MERATI A, GILIBERTO J P. Proton pump inhibitors: Review of reported risks and controversies[J]. Laryngoscope Investig Otolaryngol, 2018, 3(6): 457-462. DOI:10.1002/lio2.187.
[18]胡娟娟,郑美君,陈媛,等.关于成人咽喉反流性疾病药物治疗的再思考[J].中华耳鼻咽喉头颈外科杂志,2018,53(8):635-639.DOI:10.3760/cma.j.issn.1673-0860.2018.08.017.
HU J J, ZHENG M J, CHEN Y, et al. Reconsidering on the drug therapy of adult laryngopharyngeal reflux disease[J]. Chin J Otorhinolaryngol Head Neck Surg, 2018, 53(8):635-639.DOI:10.3760/cma.j.issn.1673-0860.2018.08.017.
[19]GUO H Y, MA H J, WANG J L. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: A meta-analysis of randomized controlled trials[J]. J Clin Gastroenterol, 2016, 50(4): 295-300. DOI:10.1097/MCG.0000000000000324.
[20]LECHIEN J R, SAUSSEZ S, SCHINDLER A, et al. Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis[J]. Laryngoscope, 2019, 129(5): 1174-1187. DOI:10.1002/lary.27591.
[21]HERBELLA F A. Gastroesophageal reflux disease: From pathophysiology to treatment[J]. World J Gastroenterol, 2010, 16(30): 3745. DOI:10.3748/wjg.v16.i30.3745.
[22]WANG L, LIU X, LIU Y L, et al. Correlation of pepsin-measured laryngopharyngeal reflux disease with symptoms and signs[J]. Otolaryngol Head Neck Surg, 2010, 143(6): 765-771. DOI:10.1016/j.otohns.2010.08.018.
[23]ZHANG C, HU Z W, YAN C, et al. Nissen fundoplication vs proton pump inhibitors for laryngopharyngeal reflux based on pH-monitoring and symptom-scale[J]. World J Gastroenterol, 2017, 23(19): 3546-3555. DOI:10.3748/wjg.v23.i19.3546.

相似文献/References:

[1]赵倩瑜,卓超,黎毅敏,等.质子泵抑制剂对危重监护病房医院获得性肺炎发展及预后的影响[J].第三军医大学学报,2013,35(23):2521.
 Zhao Qianyu,Zhuo Chao,Li Yimin,et al.Effect of proton pump inhibitors on development and prognosis of hospital-acquired pneumonia in intensive care unit[J].J Third Mil Med Univ,2013,35(21):2521.

更新日期/Last Update: 2019-11-12